146 related articles for article (PubMed ID: 20216545)
1. Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act.
Tefferi A
Bone Marrow Transplant; 2010 Mar; 45(3):419-21. PubMed ID: 20216545
[No Abstract] [Full Text] [Related]
2. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Barosi G; Bacigalupo A
Curr Opin Hematol; 2006 Mar; 13(2):74-8. PubMed ID: 16456372
[TBL] [Abstract][Full Text] [Related]
3. Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis.
Robin M; Espérou H; de Latour RP; Petropoulou AD; Xhaard A; Ribaud P; Socié G
Br J Haematol; 2010 Sep; 150(6):721-4. PubMed ID: 20618333
[No Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for myelofibrosis.
Rondelli D
Haematologica; 2008 Oct; 93(10):1449-50. PubMed ID: 18827262
[No Abstract] [Full Text] [Related]
5. Allogeneic stem cell transplantation as treatment for myelofibrosis.
Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
[TBL] [Abstract][Full Text] [Related]
6. Stem cell transplantation for myelofibrosis: a report from two Canadian centers.
Daly A; Song K; Nevill T; Nantel S; Toze C; Hogge D; Forrest D; Lavoie J; Sutherland H; Shepherd J; Hasegawa W; Lipton J; Messner H; Kiss T
Bone Marrow Transplant; 2003 Jul; 32(1):35-40. PubMed ID: 12815476
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis.
Gupta V; Kröger N; Aschan J; Xu W; Leber B; Dalley C; Sabloff M; Lipton JH; Messner H; Brune M
Bone Marrow Transplant; 2009 Sep; 44(5):317-20. PubMed ID: 19234505
[No Abstract] [Full Text] [Related]
8. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
9. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type.
Bacigalupo A; Soraru M; Dominietto A; Pozzi S; Geroldi S; Van Lint MT; Ibatici A; Raiola AM; Frassoni F; De Stefano F; Verdiani S; Casarino L; Barosi G
Bone Marrow Transplant; 2010 Mar; 45(3):458-63. PubMed ID: 19718055
[TBL] [Abstract][Full Text] [Related]
11. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
12. Modern management of myelofibrosis.
Cervantes F
Br J Haematol; 2005 Mar; 128(5):583-92. PubMed ID: 15725078
[TBL] [Abstract][Full Text] [Related]
13. Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.
Mesa RA
Curr Hematol Rep; 2003 May; 2(3):264-70. PubMed ID: 12901349
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
15. Correction of recurrent angioedema related to C1 esterase inhibitor deficiency as a secondary event following nonmyeloablative allogeneic stem cell transplantation in a patient with myelofibrosis.
Kiss TL; Messner HA; Galal A; Lipton J
Bone Marrow Transplant; 2005 Jan; 35(2):213-4. PubMed ID: 15531899
[No Abstract] [Full Text] [Related]
16. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
Ditschkowski M; Elmaagacli AH; Trenschel R; Steckel NK; Koldehoff M; Beelen DW
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1350-1. PubMed ID: 17162218
[No Abstract] [Full Text] [Related]
17. Myelofibrosis with myeloid metaplasia.
Tefferi A
N Engl J Med; 2000 Apr; 342(17):1255-65. PubMed ID: 10781623
[No Abstract] [Full Text] [Related]
18. Stem-cell transplantation for myelofibrosis.
Deeg HJ; Appelbaum FR
N Engl J Med; 2001 Mar; 344(10):775-6. PubMed ID: 11236794
[No Abstract] [Full Text] [Related]
19. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis.
Ditschkowski M; Beelen DW; Trenschel R; Koldehoff M; Elmaagacli AH
Bone Marrow Transplant; 2004 Nov; 34(9):807-13. PubMed ID: 15354205
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for myelofibrosis.
van Besien K; Deeg HJ
Semin Oncol; 2005 Aug; 32(4):414-21. PubMed ID: 16202687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]